Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07110844 · ClinicalTrials.gov registry record · Phase 2
Teclistamab-Daratumumab in AL Amyloidosis
A Phase 2 study of Amyloid Light-chain Amyloidosis, sponsored by Suzanne Lentzsch, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT07110844 is a Phase 2 study of Amyloid Light-chain Amyloidosis that is actively recruiting participants, run by Suzanne Lentzsch, MD. The registered enrollment target is 25 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07110844, a Phase 2 study of Amyloid Light-chain Amyloidosis, is actively recruiting participants, sponsored by Suzanne Lentzsch, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis. The study treatment is divided into cycles (C) and each cycle is 28 days (D). Study treatment is expected to last 6 months.
Conditions Studied
Interventions
- DRUG Teclistamab
- DRUG Daratumumab and Hyaluronidase-fihj
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-11-07 |
| Est. Completion | 2033-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07110844
The ClinicalTrials.gov registry entry for NCT07110844 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Suzanne Lentzsch, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyloid Light-chain Amyloidosis appearing as the primary indexed condition, and to 2 interventions - of which Teclistamab is the first listed.
NCT07110844 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07110844 about?
NCT07110844 is a clinical study titled "Teclistamab-Daratumumab in AL Amyloidosis". The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis. The study treatment is divided into cycles (C) and each cycle is 28 days (D). Study treatment is expected to last 6 months.
What is the current status of trial NCT07110844?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2025-11-07. Estimated completion is 2033-10.
What conditions does trial NCT07110844 study?
This clinical trial studies the following conditions: Amyloid Light-chain Amyloidosis.
What interventions are being tested in trial NCT07110844?
The interventions under investigation include: Teclistamab (DRUG), Daratumumab and Hyaluronidase-fihj (DRUG).
Who is sponsoring clinical trial NCT07110844?
This trial is sponsored by Suzanne Lentzsch, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07110844 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.